These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 35673960)
61. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. Jeon M; Kim J; Oh CE; Lee JY J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578 [TBL] [Abstract][Full Text] [Related]
62. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613 [TBL] [Abstract][Full Text] [Related]
63. Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity. Kavosh A; Ashtari F; Naghavi S; Adibi I; Shaygannejad V; Karimi Z; Arabi S; Rahimi M; Mazaheri S Mult Scler Relat Disord; 2022 May; 61():103708. PubMed ID: 35349883 [TBL] [Abstract][Full Text] [Related]
64. Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety. Lv L; Lin XQ; Chen Y; Chen HD; Zhang MX; Shao H; Tung TH; Zhu JS Hum Vaccin Immunother; 2022 Nov; 18(6):2136435. PubMed ID: 36287551 [TBL] [Abstract][Full Text] [Related]
65. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination. Lee MA; Lee C; Park JH; Lee JH J Korean Med Sci; 2022 Mar; 37(10):e50. PubMed ID: 35289135 [TBL] [Abstract][Full Text] [Related]
66. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. Maruyama A; Sawa T; Teramukai S; Katoh N J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536 [TBL] [Abstract][Full Text] [Related]
67. The vaccination status and adverse effects of COVID-19 vaccine among pregnant women in Japan in 2021. Komine-Aizawa S; Haruyama Y; Deguchi M; Hayakawa S; Kawana K; Kobashi G; Miyagi E; Yamada H; Sugiyama T J Obstet Gynaecol Res; 2022 Jul; 48(7):1561-1569. PubMed ID: 35537777 [TBL] [Abstract][Full Text] [Related]
68. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388 [TBL] [Abstract][Full Text] [Related]
69. Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review. Adiao KJB; Espiritu AI; Roque VLA; Reyes JPBT J Clin Neurosci; 2020 Feb; 72():316-321. PubMed ID: 31493998 [TBL] [Abstract][Full Text] [Related]
70. The utility of a single simple question in the evaluation of patients with myasthenia gravis. Abraham A; Breiner A; Barnett C; Katzberg HD; Bril V Muscle Nerve; 2018 Feb; 57(2):240-244. PubMed ID: 28590545 [TBL] [Abstract][Full Text] [Related]
71. Patient-acceptable symptom states in myasthenia gravis. Mendoza M; Tran C; Bril V; Katzberg HD; Barnett C Neurology; 2020 Sep; 95(12):e1617-e1628. PubMed ID: 32759200 [TBL] [Abstract][Full Text] [Related]
72. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea. Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261 [TBL] [Abstract][Full Text] [Related]
73. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. Johnston MS; Galan A; Watsky KL; Little AJ JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670 [TBL] [Abstract][Full Text] [Related]
74. COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China. Li J; Zheng Y; Zhao Y; Qi K; Lin G; Liu R; Hao H; Wang Z; Yuan Y; Gao F Neurol Sci; 2024 Jul; 45(7):2969-2976. PubMed ID: 38652194 [TBL] [Abstract][Full Text] [Related]
75. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers. Song JY; Cheong HJ; Kim SR; Lee SE; Kim SH; Noh JY; Yoon YK; Choi WS; Park DW; Sohn JW; Kim WJ; Kim MJ J Korean Med Sci; 2021 Apr; 36(15):e110. PubMed ID: 33876589 [TBL] [Abstract][Full Text] [Related]
76. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021. Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835 [TBL] [Abstract][Full Text] [Related]
77. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805 [TBL] [Abstract][Full Text] [Related]
78. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Kupersmith MJ; Latkany R; Homel P Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710 [TBL] [Abstract][Full Text] [Related]
79. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis. Chavez A; Pougnier C J Prim Care Community Health; 2021; 12():21501327211051933. PubMed ID: 34709075 [TBL] [Abstract][Full Text] [Related]
80. Use of Remdesivir in Myasthenia gravis and COVID-19. Peters BJ; Rabinstein AA; DuBrock HM Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]